PROSTATE CANCER: RISK FACTORS, SCREENING, DIAGNOSIS AND TREATMENT
AbstractProstate cancer is one of the most important cancer in men. In most cases, prostate cancer confirmed by histological and transrectal biopsy for the examination of prostatic tissue. Metastatic prostate cancer is second leading cause of death from cancer. Androgen deprivation therapy is common treatment in men with prostate cancer that may cause fatigue, increased body fatness, and loss of lean body tissue. Abiraterone acetate improved overall survival in Metastatic Castration-Resistant Prostate Cancer. Enzalutamide is a novel anti-androgen that is approved for the treatment of Metastatic Castration-Resistance Prostate Cancer after taxane-based chemotherapy. The management options include surveillance, radiotherapy, and radical prostatectomy, but there is no evidence base to evaluate the benefits of each approach. Advanced prostate cancer is managed by hormonal therapy. Active surveillance is a novel and fascinating approach to distinguish between patients who are at higher risk and need active therapy and patients who are at low risk for disease progression. This review provides a short overview of the various approaches of prostate cancer.
Article Information
9
2592-2603
632
978
English
IJPSR
P. B. Mairal * and Y. B. Mali
Department of Pharmaceutical Chemistry, Matoshri College of Pharmacy, Ekalehare, Nashik, Maharashtra, India.
poojamairal27@gmail.com
31 August 2019
30 December 2019
01 January 2020
10.13040/IJPSR.0975-8232.11(6).2592-03
01 June 2020
Download